**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 55418

**Manuscript Type:** REVIEW

**Cytomegalovirus infection after liver transplantation**

Lizaola-Mayo BC *et al*. CMV infection after liver transplantation

Blanca C Lizaola-Mayo, Eduardo A Rodriguez

**Blanca C Lizaola-Mayo,** Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ 85259, United States

**Eduardo A Rodriguez,** Division of Gastroenterology, Hepatology & Nutrition, University of Utah, Salt Lake City, UT 84132, United States

**Author contributions:** Lizaola-Mayo BC and Rodriguez EA wrote the paper.

**Corresponding author: Eduardo A Rodriguez, MD, Assistant Professor,** Division of Gastroenterology, Hepatology & Nutrition, University of Utah, 30 N 1900 E, Room 4R118, Salt Lake City, UT 84132, United States. eduardo.rodriguez@hsc.utah.edu

**Received:** March 24, 2020

**Revised:** May 28, 2020

**Accepted:** July 1, 2020

**Published online**: July 29, 2020

**Abstract**

Human cytomegalovirus (CMV) represents the most common opportunistic infection in liver transplant recipients. CMV infections in post liver transplant patients cause significant morbidity and mortality, directly affecting post-transplant outcomes. This review will provide the framework for the surveillance, diagnosis, prophylaxis and treatment of CMV in the liver transplant population.

**Key words:** Cytomegalovirus; Liver transplant; Immunosuppression; Serostatus

**Citation:** Lizaola-Mayo BC, Rodriguez EA. Cytomegalovirus infection after liver transplantation. *World J Transplant* 2020; 10(7): 183-190 URL: https://www.wjgnet.com/2220-3230/full/v10/i7/183.htm DOI: https://dx.doi.org/10.5500/wjt.v10.i7.183

**Core tip:** Cytomegalovirus (CMV) is the most common infection in the liver transplant population directly affecting posttransplant outcomes through its direct and indirect effects. The donor and recipient’s CMV serostatus represent the most important factor to determine CMV posttransplant risk, and the need for prophylaxis. Herein, we discuss and summarize the most current CMV preventive, diagnostic, and therapeutic strategies in this vulnerable cohort of patients.

**INTRODUCTION**

Cytomegalovirus (CMV) or human herpes virus 5 (HHV 5) is a member of the *Herpesviridae* family. It is a double stranded DNA virus that gives the appearance of intranuclear inclusions in infected cells[1]. The primary infection tends to happen during the first 2 decades of life[2-4]. In immunocompetent patients, the infection can be asymptomatic or self-limited. After the primary infection, the virus remains latent in the body, serving as a reservoir[5]. Reactivation and transmission are higher in susceptible individuals, either due to acquired immunodeficiency syndrome (AIDS) or secondary to induced immunosuppression like in the case of liver transplant recipients[5]. In developed countries, the seroprevalence of CMV is around 50%, and in developing countries this percentage increases up to 97%[1,3,6]. CMV is the most common opportunistic infection in liver transplant recipients, directly affecting graft survival and patient mortality[7,8]. Despite the development of diagnostic, therapeutic and prophylactic measures, up to 29% of liver transplant recipients develop CMV disease jeopardizing posttransplant outcomes[9-11].

**INFECTION PATHOPHYSIOLOGY**

Among adults, transmission occurs through exposure of bodily fluids and tissue including saliva, tears, blood and transplanted grafts[12]. The primary infection happens in mucosal epithelial cells and the virus disseminates through circulating CD14+ monocytes[13]. After the primary infection, the virus remains latent in lymphoid and myeloid cells. In liver transplant recipients without prophylaxis, CMV infection tends to occur within the first 3 mo after transplantation[4]. CMV reactivation or infection is directly affected by the serologic status of the donor and recipient, degree of immunosuppression and prophylaxis[14]. CMV has a predilection to attack the transplanted allograft amongst other organs – causing hepatitis in liver recipients (mainly infecting hepatocytes and macrophages)[15]. It is unclear why CMV tends to attack the transplanted graft, however, it is believed that this occurs as the organ serves as a reservoir that harbors latent CMV which is undetected by the impaired immune system[9]. Following transplantation, CMV infection reactivates from latency, starts viral replication mainly in lymphoid-rich organs with ultimately disseminates through the blood stream to other organs[16].

**RISK FACTORS**

The biggest risk factor in liver transplant recipients that increases the likelihood of developing CMV disease is the recipient’s CMV-seronegative status[17]. CMV infection has a reported incidence of 78%-88% in seronegative recipients (R-) obtaining a seropositive organ (D+) without prophylaxis. This percentage decreases to 13% in seronegative recipient from seronegative donors[8,18]. Immunosuppressant drugs block T-cell function and cause severe lymphopenia, increasing the risk of CMV after liver transplantation[19,20]. A higher risk has been seen in patients receiving higher doses of maintenance immunosuppression[21]. The use of lymphocyte-depleting agents like alemtuzuman, muromonab-CD3 and anti-thymocyte globulins has been identified as a risk aswell[22,23]. In contrast, the lowest risk has been seen when utilizing sirolimus and everolimus (mTOR inhibitors)[21,24]. The use of lymphocyte-depleting antibodies to treat allograft rejection, has been associated with an increased risk for CMV infection too[25]. The risk of CMV disease in liver transplant recipients is higher than in kidney recipients and lower than lung, small intestine and simultaneous heart-lung recipients[26-29]. Other risk factors include: donor and/or recipient advanced age, HLA mismatch, immediate graft rejection by itself, impaired humoral immunity and coinfection with other herpes viruses (HSV 6 and 7)[10,30,31].

**SEROLOGIC STATUS**

Prior to transplantation, all candidates and donors must be tested for CMV using CMV-IgG serology[7]. The presence of CMV IgG antibodies through previous exposure catalogs recipients and donors as seropositive[7]. Recipients who are CMV seronegative have the highest risk of CMV infection when receiving a CMV-positive organ (D+/R-) with rates up to 88% without prophylaxis[32]. A moderate risk is seen in seropositive recipients receiving a seropositive organ (D+/R+)[33]. The lowest risk is in seronegative recipients receiving seronegative organs (D-/R-). This last group may still acquire the infection from person to person or from transfused blood products[17]. Amongst CMV-seropositive recipients, the risk is higher when receiving a CMV+ organ, likely due to superinfection (Table 1).

**CLINICAL MANIFESTATIONS**

Based on the recently published American Society of Transplantation CMV in solid organ transplant recipient guidelines[7], it is important to standardize disease definitions: CMV infection is the presence of CMV replication regardless of symptomatology. CMV replication can be detected by nucleic acid testing (NAT), antigen testing or viral culture[12]. CMV disease is defined as CMV infection accompanied by clinical signs and symptoms. Asymptomatic CMV infection is CMV replication without symptomatology[12]. CMV syndrome is characterized by the detection of CMV in blood plus at least two of the following: Fever ≥ 38 °C for at least 48 h, new or increased malaise or fatigue, leukopenia or neutropenia on two separate measurements, 5% atypical lymphocytes, thrombocytopenia and transaminitis to three times upper normal limit (ULN)[7,9].

Most CMV cases (60%) in post liver transplant patients present as a mononucleosis-like syndrome (fevers, myalgias, arthralgias and malaise) along with hematologic abnormalities and hepatitis[34]. CMV hepatitis normally presents with jaundice, mixed hepatocellular and cholestatic elevation of liver chemistries (within 3 × ULN), and documented viral presence in the liver tissue[35]. This presentation, may be confused with allograft rejection or other causes of hepatitis[36]. Few cases of fulminant and granulomatous hepatitis in the setting of CMV infections have been described as well[37-39]. Gastrointestinal CMV disease is also common in liver transplant recipients; it is defined as the presence of upper and or lower gastrointestinal (GI) symptoms with documented CMV in tissue. Serum presence of CMV alone is not sufficient for diagnosis of CMV GI disease. It tends to manifest with odynophagia, dysphagia, nausea, vomiting, epigastric pain, bloating, diarrhea and hematochezia[40]. The colon is reportedly the most common GI site to be involved (94% of cases)[41-43].

CMV infection has been related with a four-fold increased risk of acute and chronic allograft rejection through the potentiation of alloantigens[44]. CMV also has immunosuppressive effects through the impairment of CD4 T cells and macrophages - it also decreases the levels of interleukin 1 and 2 and increases the levels of interferon alpha. All these indirect effects increase the risk of invasive fungal infections, bacteremia, EBV-associated posttransplant lymphoproliferative disease and cardiovascular disease[44,45]. Thrombosis of the graft has also been described due to the proinflammatory state that CMV infection causes[25,31]. It may even facilitate reactivation and replication of hepatitis C virus[46].

**DIAGNOSIS**

Serologic diagnosis of the donor and recipient is paramount due to its significant implications in posttransplant outcomes. In the solid organ transplantation cohort, IgM and IgG antibodies have a sensitivity of 90%, antigenemia 80% and CMV PCR of 84% to 100%[47]. PCR is the preferred CMV detection method in liver transplant patients[48].

The diagnosis of CMV disease in liver transplant recipients is made through the identification of clinical manifestations including fever, fatigue, malaise, leukopenia, thrombocytopenia and elevation of liver enzymes plus identification of CMV viremia and detection of the virus in target organs[12]. Liver biopsy may be warranted due to the increased risk for allograft rejection in the setting of CMV infection[48]. The main diagnostic tests utilized are viral culture in cells, detection of viral nucleic acid through PCR and identification of viral proteins through antigenemia essays[16]. Urine CMV detection has a poor correlation with CMV disease as it usually represents viral shedding, however it has been identified as one of the first methods to identify CMV replication in CMV seronegative recipients from positive donors[49]. Whole blood has been identified to be superior over plasma, peripheral blood leukocytes and peripheral blood mononuclear cells for the quantification of CMV DNA by PCR[50].

As mentioned before, the gastrointestinal tract is the second most common target for CMV infection in the liver transplant population. Endoscopic evaluation of the large intestine with terminal ileum intubation with biopsies is recommended as isolated ileal involvement in the setting of invasive gastrointestinal CMV infection has been reported[51,52]. Endoscopic findings vary from mucosal inflammation to severe ulcerations with the characteristic diagnostic inclusion bodies seen from biopsies taken from the ulcer base[40].

**THERAPY**

Due to its direct and indirect effects, CMV infection prevention is a major strategy in post liver transplant patients. With the use of prophylaxis against CMV, there has been a reported reduction of CMV infection up to 80% during the first 90 d after transplant[53]. Amongst D+/R- liver transplant patients, CMV prophylaxis has shown to be superior to preemptive therapy[54,55]. CMV prophylaxis should be started within the first 10 days after transplant[7].

***Prophylaxis***

Oral Valganciclovir and intravenous (IV) Ganciclovir are the antiviral drugs used for CMV prophylaxis[56]. A noverl viral terminase inhibitor called Letenovir has been recently approved as a prophylactic drug in hematopoietic stem cell transplantation and is under a clinical trial in kidney transplant CMV D+/R- patients (ClinicalTrials.gov NCT03443869)[57]. To our knowledge, this drug has not been studied in the liver transplant cohort. Studies have shown comparable safety and efficacy between ganciclovir and valganciclovir[58]. Valganciclovir has not been approved for CMV prophylaxis by the U.S. Food and Drug Administration due to a subgroup analysis revealing higher rates of tissue invasive CMV disease in liver transplant patients treated with this drug[56]. Regardless, as an oral drug with improved bioavailability Valganciclovir is still the preferred prophylactic drug over IV Ganciclovir in liver recipients[59]. The recommended valganciclovir dose is 900 mg per day which needs to be adjusted in patients with kidney disease[60]. The ideal duration in high-risk patients (D+/R-) has not been specifically studied in liver transplant patients, however due to the increased risk of postprophylaxis delayed-CMV disease seen during the first six months, and the decreased rate of CMV infection in a kidney transplant population receiving CMV prophylaxis; most transplant centers apply the prophylaxis for six months[56,60]. In CMV R+ patients, prophylaxis is recommended to last 3 mo and in D-/R- prophylaxis is not indicated. After conclusion of CMV prophylaxis, it is important to monitor for postprophylaxis delayed-onset CMV disease weekly for three months[7].

***Preemptive therapy***

Preemptive therapy should be started as soon as CMV viremia (> threefold increase in serum CMV PCR) is identified[61]. Oral valganciclovir is 900 mg twice a day to be adjusted for renal impairment or IV ganciclovir 5 mg/kg twice a day have a similar reported treatment efficacy of up to 85% in posttransplant patients[58] (Table 2). Treatment is advised to be continued until there is a documented negative quantitative CMV PCR. Due to its high sensitivity it is not necessary to confirm two consecutive negative tests anymore[48,62].

***CMV disease therapy***

For stablished CMV disease, IV ganciclovir (5 mg/kg twice a day) is recommended for severe disease. For mild to moderate disease, oral valganciclovir [900 mg twice a day (renally-dosed)] has shown to be equally effective to ganciclovir[58]. Foscarnet and cidofovir are considered second line drugs due to its nephrotoxic effects[63]. Therapy should be given for at least 2 wk and discontinuation is based upon virological clearance and resolution of symptomatology[62,64]. Persistent viremia after therapy and extensive involvement of the gastrointestinal tract have been identified as risk factors for CMV relapse[65]. CMV seroconversion, viral load, treatment duration, maintenance therapy and endoscopic findings at the end of therapy are not significantly associated with CMV relapse[66].

CMV resistance to antiviral drugs is an emerging problem. Resistance happens through mutations of the viral DNA polymerase UL54 and the thymidine kinase UL97[67]. The incidence of CMV resistance in liver transplant patients is not well defined, however it is believed that in solid organ transplants in general it is around 7% in high risk patients[68,69]. When ganciclovir and valganciclovir are shown to be ineffective due to resistance, patient should be treated with combination therapy, foscarnet and cidofovir or experimental treatments[70].

**CONCLUSION**

CMV is the most common opportunistic infection in liver transplant patients. Its direct and indirect effects directly impact post liver transplant outcomes and patient mortality. Pre-transplant donor and recipient serological identification are key to determine posttransplant CMV risk and prophylaxis need. Current therapies have shown to be effective, however ongoing trials are focusing on prevention through vaccines and novel drugs for resistant cases.

**REFERENCES**

1 **Beam E**, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. *Curr Infect Dis Rep* 2012; **14**: 633-641 [PMID: 22992839 DOI: 10.1007/s11908-012-0292-2]

2 **Bate SL**, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. *Clin Infect Dis* 2010; **50**: 1439-1447 [PMID: 20426575 DOI: 10.1086/652438]

3 **Cannon MJ**, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev Med Virol* 2010; **20**: 202-213 [PMID: 20564615 DOI: 10.1002/rmv.655]

4 **Razonable RR**, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. *Herpes* 2003; **10**: 60-65 [PMID: 14759337]

5 **Meesing A**, Razonable RR. New Developments in the Management of Cytomegalovirus Infection After Transplantation. *Drugs* 2018; **78**: 1085-1103 [PMID: 29961185 DOI: 10.1007/s40265-018-0943-1]

6 **Zuhair M**, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. *Rev Med Virol* 2019; **29**: e2034 [PMID: 30706584 DOI: 10.1002/rmv.2034]

7 **Razonable RR**, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019; **33**: e13512 [PMID: 30817026 DOI: 10.1111/ctr.13512]

8 **Paya CV**, Marin E, Keating M, Dickson R, Porayko M, Wiesner R. Solid organ transplantation: results and implications of acyclovir use in liver transplants. *J Med Virol* 1993; **Suppl 1**: 123-127 [PMID: 8245877 DOI: 10.1002/jmv.1890410524]

9 **Humar A**, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. *Am J Transplant* 2009; **9 Suppl 4**: S78-S86 [PMID: 20070700 DOI: 10.1111/j.1600-6143.2009.02897.x]

10 **Singh N**, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? *Liver Transpl* 2005; **11**: 700-704 [PMID: 15915496 DOI: 10.1002/lt.20417]

11 **Gane E**, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. *Lancet* 1997; **350**: 1729-1733 [PMID: 9413463 DOI: 10.1016/s0140-6736(97)05535-9]

12 **Ljungman P**, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. *Clin Infect Dis* 2017; **64**: 87-91 [PMID: 27682069 DOI: 10.1093/cid/ciw668]

13 **Collins-McMillen D**, Buehler J, Peppenelli M, Goodrum F. Molecular Determinants and the Regulation of Human Cytomegalovirus Latency and Reactivation. *Viruses* 2018; **10**: [PMID: 30127257 DOI: 10.3390/v10080444]

14 **Winston DJ**, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. *Clin Infect Dis* 1995; **21**: 1077-89; quiz 1090-1 [PMID: 8589125 DOI: 10.1093/clinids/21.5.1077]

15 **Razonable R**. Direct and indirect effects of cytomegalovirus: can we prevent them? *Enferm Infecc Microbiol Clin* 2010; **28**: 1-5 [PMID: 20022410 DOI: 10.1016/j.eimc.2009.07.008]

16 **Razonable RR**, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. *J Clin Microbiol* 2002; **40**: 746-752 [PMID: 11880387 DOI: 10.1128/jcm.40.3.746-752.2002]

17 **Manuel O**, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. *Clin Infect Dis* 2013; **56**: 817-824 [PMID: 23196955 DOI: 10.1093/cid/cis993]

18 **Lautenschlager I**, Halme L, Höckerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. *Transpl Infect Dis* 2006; **8**: 21-30 [PMID: 16623817 DOI: 10.1111/j.1399-3062.2006.00122.x]

19 **Gardiner BJ**, Nierenberg NE, Chow JK, Ruthazer R, Kent DM, Snydman DR. Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients. *Clin Infect Dis* 2018; **67**: 1395-1402 [PMID: 29635432 DOI: 10.1093/cid/ciy295]

20 **Meesing A**, Abraham RS, Razonable RR. Clinical Correlation of Cytomegalovirus Infection With CMV-specific CD8+ T-cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients. *Transplantation* 2019; **103**: 832-838 [PMID: 30086091 DOI: 10.1097/tp.0000000000002396]

21 **Brennan DC**, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. *Am J Transplant* 2011; **11**: 2453-2462 [PMID: 21812923 DOI: 10.1111/j.1600-6143.2011.03674.x]

22 **Gala-Lopez BL**, Senior PA, Koh A, Kashkoush SM, Kawahara T, Kin T, Humar A, Shapiro AM. Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation. *Am J Transplant* 2011; **11**: 2708-2714 [PMID: 21906252 DOI: 10.1111/j.1600-6143.2011.03724.x]

23 **Portela D**, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Paya CV. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. *J Infect Dis* 1995; **171**: 1014-1018 [PMID: 7706779 DOI: 10.1093/infdis/171.4.1014]

24 **Pascual J**, Royuela A, Fernández AM, Herrero I, Delgado JF, Solé A, Guirado L, Serrano T, de la Torre-Cisneros J, Moreno A, Cordero E, Gallego R, Lumbreras C, Aguado JM; Spanish Society of Transplantation Virological and Immune Response Investigation Study Group. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. *Transpl Infect Dis* 2016; **18**: 819-831 [PMID: 27600985 DOI: 10.1111/tid.12601]

25 **Razonable RR**, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. *J Infect Dis* 2001; **184**: 1461-1464 [PMID: 11709790 DOI: 10.1086/324516]

26 **Ambrose T**, Sharkey LM, Louis-Auguste J, Rutter CS, Duncan S, English S, Gkrania-Klotsas E, Carmichael A, Woodward JM, Russell N, Massey D, Butler A, Middleton S. Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation. *Transplant Proc* 2016; **48**: 492-496 [PMID: 27109985 DOI: 10.1016/j.transproceed.2015.09.070]

27 **Nagai S**, Mangus RS, Anderson E, Ekser B, Kubal CA, Fridell JA, Tector AJ. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases. *Transplantation* 2016; **100**: 451-460 [PMID: 26247555 DOI: 10.1097/tp.0000000000000832]

28 **Beam E**, Lesnick T, Kremers W, Kennedy CC, Razonable RR. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis. *Clin Transplant* 2016; **30**: 270-278 [PMID: 26701733 DOI: 10.1111/ctr.12686]

29 **Humar A**, Gregson D, Caliendo AM, McGeer A, Malkan G, Krajden M, Corey P, Greig P, Walmsley S, Levy G, Mazzulli T. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. *Transplantation* 1999; **68**: 1305-1311 [PMID: 10573068 DOI: 10.1097/00007890-199911150-00015]

30 **Singh N**, Wagener MM. Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. *Ann Intern Med* 2006; **144**: 456-7; author reply 457 [PMID: 16549866 DOI: 10.7326/0003-4819-144-6-200603210-00024]

31 **Razonable RR**. Cytomegalovirus infection after liver transplantation: current concepts and challenges. *World J Gastroenterol* 2008; **14**: 4849-4860 [PMID: 18756591 DOI: 10.3748/wjg.14.4849]

32 **Manuel O**, Pang XL, Humar A, Kumar D, Doucette K, Preiksaitis JK. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. *J Infect Dis* 2009; **199**: 1621-1628 [PMID: 19385736 DOI: 10.1086/598952]

33 **Fernández-Ruiz M**, Giménez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, Montejo M, Paez-Vega A, Cantisán S, Torre-Cisneros J, Fortún J, Andrés A, San Juan R, López-Medrano F, Navarro D, Aguado JM; Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. *Clin Microbiol Infect* 2019; **25**: 381.e1-381.e10 [PMID: 29803844 DOI: 10.1016/j.cmi.2018.05.010]

34 **Razonable RR**, Emery VC; 11th Annual Meeting of the IHMF (International Herpes Management Forum). Management of CMV infection and disease in transplant patients. 27-29 February 2004. *Herpes* 2004; **11**: 77-86 [PMID: 15960905]

35 **Cohen JI**, Corey GR. Cytomegalovirus infection in the normal host. *Medicine (Baltimore)* 1985; **64**: 100-114 [PMID: 2983175 DOI: 10.1097/00005792-198503000-00003]

36 **Paya CV**, Hermans PE, Wiesner RH, Ludwig J, Smith TF, Rakela J, Krom RA. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. *J Infect Dis* 1989; **160**: 752-758 [PMID: 2553824 DOI: 10.1093/infdis/160.5.752]

37 **Shusterman NH**, Frauenhoffer C, Kinsey MD. Fatal massive hepatic necrosis in cytomegalovirus mononucleosis. *Ann Intern Med* 1978; **88**: 810-812 [PMID: 208441 DOI: 10.7326/0003-4819-88-6-810]

38 **Tjwa M**, De Hertogh G, Neuville B, Roskams T, Nevens F, Van Steenbergen W. Hepatic fibrin-ring granulomas in granulomatous hepatitis: report of four cases and review of the literature. *Acta Clin Belg* 2001; **56**: 341-348 [PMID: 11881318 DOI: 10.1179/acb.2001.051]

39 **Clarke J**, Craig RM, Saffro R, Murphy P, Yokoo H. Cytomegalovirus granulomatous hepatitis. *Am J Med* 1979; **66**: 264-269 [PMID: 218449 DOI: 10.1016/0002-9343(79)90543-6]

40 **You DM**, Johnson MD. Cytomegalovirus infection and the gastrointestinal tract. *Curr Gastroenterol Rep* 2012; **14**: 334-342 [PMID: 22588614 DOI: 10.1007/s11894-012-0266-4]

41 **Patra S**, Samal SC, Chacko A, Mathan VI, Mathan MM. Cytomegalovirus infection of the human gastrointestinal tract. *J Gastroenterol Hepatol* 1999; **14**: 973-976 [PMID: 10530492 DOI: 10.1046/j.1440-1746.1999.01986.x]

42 **Lee CY**, Chen YH, Lu PL. Reactivated cytomegalovirus proctitis in an immunocompetent patient presenting as nosocomial diarrhea: a case report and literature review. *BMC Infect Dis* 2017; **17**: 113 [PMID: 28143418 DOI: 10.1186/s12879-017-2218-y]

43 **Jacob S**, Zayyani NR. Cytomegalovirus colitis masquerading as rectal malignancy in an immunocompetent patient. *Indian J Pathol Microbiol* 2015; **58**: 80-82 [PMID: 25673600 DOI: 10.4103/0377-4929.151195]

44 **Razonable RR**, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. *Am J Transplant* 2013; **13 Suppl 4**: 93-106 [PMID: 23465003 DOI: 10.1111/ajt.12103]

45 **Aguilera V**, Di Maira T, Conde I, Fornés-Ferrer V, Vinaixa C, Pallarés C, Carvalho-Gomes A, Cubells A, García M, Rubín Á, Benlloch S, Gonzalez-Dieguez L, Molina JM, Puchades L, López-Labrador FX, Prieto M, Berenguer M. Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. *Transpl Int* 2018; **31**: 649-657 [PMID: 29493818 DOI: 10.1111/tri.13145]

46 **Mendez JC**, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, Ilstrup D, Paya CV. Human beta-herpesvirus interactions in solid organ transplant recipients. *J Infect Dis* 2001; **183**: 179-184 [PMID: 11120923 DOI: 10.1086/317929]

47 **Halling VW**, Maine GT, Groettum CM, Wilson JA, Spesard J, Brojanac S, Combs B, Wachta D, Holas C, Wilson T, Wang D, Tomazic-Allen S, Lazzarotto T, Landini MP, Jevremovic-Simovic S, Wiesner RH, Paya CV, Smith TF. Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. *Transplantation* 2001; **71**: 395-397 [PMID: 11233899 DOI: 10.1097/00007890-200102150-00009]

48 **Dioverti MV**, Razonable RR. Cytomegalovirus. *Microbiol Spectr* 2016; **4**: [PMID: 27726793 DOI: 10.1128/microbiolspec.DMIH2-0022-2015]

49 **Patel R**, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, Paya CV. Cytomegalovirus prophylaxis in solid organ transplant recipients. *Transplantation* 1996; **61**: 1279-1289 [PMID: 8629285 DOI: 10.1097/00007890-199605150-00001]

50 **Razonable RR**, Brown RA, Wilson J, Groettum C, Kremers W, Espy M, Smith TF, Paya CV. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. *Transplantation* 2002; **73**: 968-973 [PMID: 11923702 DOI: 10.1097/00007890-200203270-00025]

51 **Lepinski SM**, Hamilton JW. Isolated cytomegalovirus ileitis detected by colonoscopy. *Gastroenterology* 1990; **98**: 1704-1706 [PMID: 2159931 DOI: 10.1016/0016-5085(90)91112-j]

52 **Navaneethan U**, Venkatesh PG, Wang J. Cytomegalovirus ileitis in a patient after liver transplantation-differentiating from de novo IBD. *J Crohns Colitis* 2011; **5**: 354-359 [PMID: 21683307 DOI: 10.1016/j.crohns.2011.01.010]

53 **Lowance D**, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. *N Engl J Med* 1999; **340**: 1462-1470 [PMID: 10320384 DOI: 10.1056/nejm199905133401903]

54 **Bodro M**, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. *Liver Transpl* 2012; **18**: 1093-1099 [PMID: 22532316 DOI: 10.1002/lt.23460]

55 **Simon P**, Sasse M, Laudi S, Petroff D, Bartels M, Kaisers UX, Bercker S. Two strategies for prevention of cytomegalovirus infections after liver transplantation. *World J Gastroenterol* 2016; **22**: 3412-3417 [PMID: 27022223 DOI: 10.3748/wjg.v22.i12.3412]

56 **Paya C**, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant* 2004; **4**: 611-620 [PMID: 15023154 DOI: 10.1111/j.1600-6143.2004.00382.x]

57 **Marty FM**, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. *N Engl J Med* 2017; **377**: 2433-2444 [PMID: 29211658 DOI: 10.1056/NEJMoa1706640]

58 **Asberg A**, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant* 2007; **7**: 2106-2113 [PMID: 17640310 DOI: 10.1111/j.1600-6143.2007.01910.x]

59 **Levitsky J**, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. *Am J Transplant* 2008; **8**: 158-161 [PMID: 17973961 DOI: 10.1111/j.1600-6143.2007.02026.x]

60 **Humar A**, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. *Am J Transplant* 2010; **10**: 1228-1237 [PMID: 20353469 DOI: 10.1111/j.1600-6143.2010.03074.x]

61 **Hirsch HH**, Lautenschlager I, Pinsky BA, Cardeñoso L, Aslam S, Cobb B, Vilchez RA, Valsamakis A. An international multicenter performance analysis of cytomegalovirus load tests. *Clin Infect Dis* 2013; **56**: 367-373 [PMID: 23097587 DOI: 10.1093/cid/cis900]

62 **Sia IG**, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. *J Infect Dis* 2000; **181**: 717-720 [PMID: 10669361 DOI: 10.1086/315242]

63 **Avery RK**, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, Trollinger B, Shah P, Ambinder R, Neofytos D, Ostrander D, Forman M, Valsamakis A. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. *Transplantation* 2016; **100**: e74-e80 [PMID: 27495775 DOI: 10.1097/tp.0000000000001418]

64 **Asberg A**, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, Bignamini A, Töz H, Dittmer I, Montejo M, Hartmann A; VICTOR Study Group. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. *Am J Transplant* 2009; **9**: 1205-1213 [PMID: 19422345 DOI: 10.1111/j.1600-6143.2009.02617.x]

65 **Eid AJ**, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant* 2010; **10**: 157-161 [PMID: 19889123 DOI: 10.1111/j.1600-6143.2009.02861.x]

66 **Gardiner BJ**, Chow JK, Price LL, Nierenberg NE, Kent DM, Snydman DR. Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients. *Clin Infect Dis* 2017; **65**: 2000-2007 [PMID: 29020220 DOI: 10.1093/cid/cix696]

67 **Emery VC**, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. *Proc Natl Acad Sci USA* 2000; **97**: 8039-8044 [PMID: 10859361 DOI: 10.1073/pnas.140123497]

68 **Limaye AP**, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. *Lancet* 2000; **356**: 645-649 [PMID: 10968438 DOI: 10.1016/s0140-6736(00)02607-6]

69 **Myhre HA**, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. *Transplantation* 2011; **92**: 217-223 [PMID: 21685829 DOI: 10.1097/TP.0b013e31821fad25]

70 **Czarnecka P**, Czarnecka K, Tronina O, Durlik M. Cytomegalovirus Disease After Liver Transplant-A Description of a Treatment-Resistant Case: A Case Report and Literature Review. *Transplant Proc* 2018; **50**: 4015-4022 [PMID: 30577306 DOI: 10.1016/j.transproceed.2018.05.014]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** American Association for the Study of Liver Diseases; American College of Gastroenterology; and American Society of Gastrointestinal Endoscopy.

**Peer-review started:** March 24, 2020

**First decision:** April 22, 2020

**Article in press:** July 1, 2020

**Specialty type:** Transplantation

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Liatsos GD **S-Editor:** Gong ZM **L-Editor: E-Editor:**

**Table 1 Risk of cytomegalovirus infection based on donor and recipient serostatus**

|  |  |  |  |
| --- | --- | --- | --- |
| **Donor** | **Recipient** | **Risk** | **Recommended prophylaxis length** |
| Positive | Negative | Highest | 6 mo |
| Positive | Positive | Higher | 3 mo |
| Negative | Positive | Moderate | 3 mo |
| Negative | Negative | Low | Not recommended |

**Table 2 Antiviral drugs for cytomegalovirus prophylaxis and treatment in liver transplant patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug** | **Route** | **Prophylaxis dose** | **Treatment dose** | **Side effects** |
| Ganciclovir | IV | 5 mg/kg daily | 5 mg/kg twice a day | Bone marrow suppression |
| Valganciclovir | Oral | 900 mg once a day | 900 mg twice a day | Leukopenia |
| Foscarnet | IV | - | 60 mg/kg every 8 h or 90 mg/kg every 12 h | Nephrotoxicity |
| Cidofovir | IV | - | 5 mg/kg weekly × 2, then every 2 wk | Nephrotoxicity |